Supernus Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell SUPN and other ETFs, options, and stocks.

About SUPN

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. 

CEO
Jack A. Khattar
CEOJack A. Khattar
Employees
778
Employees778
Headquarters
Rockville, Maryland
HeadquartersRockville, Maryland
Founded
2005
Founded2005
Employees
778
Employees778

SUPN Key Statistics

Market cap
3.12B
Market cap3.12B
Price-Earnings ratio
-79.21
Price-Earnings ratio-79.21
Dividend yield
Dividend yield
Average volume
1.13M
Average volume1.13M
High today
$54.69
High today$54.69
Low today
$52.27
Low today$52.27
Open price
$53.56
Open price$53.56
Volume
801.11K
Volume801.11K
52 Week high
$59.68
52 Week high$59.68
52 Week low
$29.16
52 Week low$29.16

Stock Snapshot

With a market cap of 3.12B, Supernus Pharmaceuticals(SUPN) trades at $54.35. The stock has a price-to-earnings ratio of -79.21.

As of 2026-03-10, Supernus Pharmaceuticals(SUPN) stock has fluctuated between $52.27 and $54.69. The current price stands at $54.35, placing the stock +4.0% above today's low and -0.6% off the high.

Supernus Pharmaceuticals(SUPN) shares are trading with a volume of 801.11K, against a daily average of 1.13M.

During the past year, Supernus Pharmaceuticals(SUPN) stock moved between $29.16 at its lowest and $59.68 at its peak.

During the past year, Supernus Pharmaceuticals(SUPN) stock moved between $29.16 at its lowest and $59.68 at its peak.

SUPN News

TipRanks 6h
Top Supernus Director Quietly Unloads a Major Chunk of Stock

New insider activity at Supernus Pharmaceuticals ( (SUPN) ) has taken place on March 9, 2026. Director Georges Gemayel of Supernus Pharmaceuticals has executed...

Simply Wall St 3d
Assessing Supernus Pharmaceuticals Valuation After Q4 Results And 2026 Guidance Update

Advertisement Why Supernus Pharmaceuticals Stock Is On Investors’ Radar This Week Supernus Pharmaceuticals (SUPN) has drawn fresh attention after releasing fo...

Assessing Supernus Pharmaceuticals Valuation After Q4 Results And 2026 Guidance Update
TipRanks 6d
Supernus Pharmaceuticals Braces for 2025 U.S. Drug Pricing Orders and MFN Rules That Threaten Revenues and Global Expansion

Supernus Pharmaceuticals (SUPN) has disclosed a new risk, in the Employment / Personnel category. Supernus Pharmaceuticals faces heightened uncertainty as 2025...

Analyst ratings

83%

of 6 ratings
Buy
83.3%
Hold
16.7%
Sell
0%

People also own

Based on the portfolios of people who own SUPN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.